JP2021511363A5 - - Google Patents

Info

Publication number
JP2021511363A5
JP2021511363A5 JP2020540798A JP2020540798A JP2021511363A5 JP 2021511363 A5 JP2021511363 A5 JP 2021511363A5 JP 2020540798 A JP2020540798 A JP 2020540798A JP 2020540798 A JP2020540798 A JP 2020540798A JP 2021511363 A5 JP2021511363 A5 JP 2021511363A5
Authority
JP
Japan
Prior art keywords
triazine
amino
pyrrolo
trifluoromethyl
fluoro
Prior art date
Application number
JP2020540798A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019147782A5 (https=
JP7307734B2 (ja
JP2021511363A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/014918 external-priority patent/WO2019147782A1/en
Publication of JP2021511363A publication Critical patent/JP2021511363A/ja
Publication of JP2021511363A5 publication Critical patent/JP2021511363A5/ja
Publication of JPWO2019147782A5 publication Critical patent/JPWO2019147782A5/ja
Application granted granted Critical
Publication of JP7307734B2 publication Critical patent/JP7307734B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020540798A 2018-01-26 2019-01-24 キナーゼ阻害剤としてのアミノピロロトリアジン Active JP7307734B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862622415P 2018-01-26 2018-01-26
US62/622,415 2018-01-26
PCT/US2019/014918 WO2019147782A1 (en) 2018-01-26 2019-01-24 Aminopyrrolotriazines as kinase inhibitors

Publications (4)

Publication Number Publication Date
JP2021511363A JP2021511363A (ja) 2021-05-06
JP2021511363A5 true JP2021511363A5 (https=) 2022-01-28
JPWO2019147782A5 JPWO2019147782A5 (https=) 2022-01-28
JP7307734B2 JP7307734B2 (ja) 2023-07-12

Family

ID=65363405

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020540798A Active JP7307734B2 (ja) 2018-01-26 2019-01-24 キナーゼ阻害剤としてのアミノピロロトリアジン

Country Status (16)

Country Link
US (1) US11618753B2 (https=)
EP (1) EP3743430B1 (https=)
JP (1) JP7307734B2 (https=)
KR (1) KR102759231B1 (https=)
CN (1) CN112262139B (https=)
AR (1) AR114186A1 (https=)
AU (1) AU2019211382B2 (https=)
BR (1) BR112020014516A2 (https=)
CA (1) CA3088548A1 (https=)
EA (1) EA202091777A1 (https=)
ES (1) ES2959399T3 (https=)
IL (1) IL276269A (https=)
MX (1) MX2020007531A (https=)
SG (1) SG11202007035YA (https=)
TW (1) TW201940485A (https=)
WO (1) WO2019147782A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA47460A (fr) 2017-02-13 2019-12-18 Bristol Myers Squibb Co Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
HUE058292T2 (hu) 2017-10-30 2022-07-28 Bristol Myers Squibb Co Aminoimidazopiridazinok mint kináz inhibitorok
AU2019339355A1 (en) 2018-09-13 2021-05-13 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
KR102906523B1 (ko) 2018-09-13 2025-12-30 브리스톨-마이어스 스큅 컴퍼니 수용체-상호작용 단백질 키나제 1 (ripk1) 억제제로서의 1h-인다졸 카르복스아미드
ES2969756T3 (es) 2019-10-03 2024-05-22 Bristol Myers Squibb Co Indazol carboxamidas como inhibidores de cinasas
JPWO2021157596A1 (https=) * 2020-02-07 2021-08-12
WO2022007921A1 (zh) * 2020-07-10 2022-01-13 北京范恩柯尔生物科技有限公司 三嗪类化合物及其组合物和用途
CN111925345B (zh) * 2020-08-21 2023-09-29 上海科利生物医药有限公司 一种手性2-氨甲基四氢呋喃的制备方法
AR123793A1 (es) 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas
JPWO2022172889A1 (https=) * 2021-02-10 2022-08-18
CN113563214B (zh) * 2021-07-06 2024-02-02 山东鲁泰控股集团有限公司石墨烯高分子复合材料研发中心 一种氨基乙酸的合成方法
CN113527220A (zh) * 2021-07-26 2021-10-22 京博农化科技有限公司 一种脱硫丙硫菌唑异构体的合成方法
CN116574053B (zh) * 2022-06-21 2026-04-14 中国药科大学 Ripk1激酶靶点抑制剂及其医药用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2627839C (en) 2005-11-02 2014-08-19 Bayer Healthcare Ag Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
EP2385053B1 (en) * 2005-11-17 2013-10-02 OSI Pharmaceuticals, Inc. Intermediates for the preparation of fused bicyclic mTOR inhibitors
KR101461680B1 (ko) 2005-12-02 2014-11-19 바이엘 헬스케어 엘엘씨 과다-증식성 장애 및 맥관형성과 관련된 질환의 치료에유용한 치환된 4-아미노-피롤로트리아진 유도체
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
GB2467670B (en) * 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
EP2424368B1 (en) 2009-04-29 2014-12-31 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
HRP20160967T1 (hr) 2009-10-06 2016-10-07 Millennium Pharmaceuticals, Inc. Heterociklički spojevi korisni kao pdk1 inhibitori
CN102918045A (zh) 2010-03-31 2013-02-06 百时美施贵宝公司 作为蛋白激酶抑制剂的取代的吡咯并三嗪
WO2014047024A1 (en) 2012-09-18 2014-03-27 Bristol-Myers Squibb Company Iap antagonists
WO2015054358A1 (en) 2013-10-11 2015-04-16 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US10023576B2 (en) * 2014-10-22 2018-07-17 Bristol-Myers Squibb Company Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors
US10214537B2 (en) * 2014-10-22 2019-02-26 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds
MD3436461T2 (ro) 2016-03-28 2024-05-31 Incyte Corp Compuși pirolotriazină ca inhibitori TAM
WO2018017435A1 (en) 2016-07-22 2018-01-25 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
MA47460A (fr) 2017-02-13 2019-12-18 Bristol Myers Squibb Co Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
HUE058292T2 (hu) 2017-10-30 2022-07-28 Bristol Myers Squibb Co Aminoimidazopiridazinok mint kináz inhibitorok
AU2019339355A1 (en) 2018-09-13 2021-05-13 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
KR102906523B1 (ko) 2018-09-13 2025-12-30 브리스톨-마이어스 스큅 컴퍼니 수용체-상호작용 단백질 키나제 1 (ripk1) 억제제로서의 1h-인다졸 카르복스아미드

Similar Documents

Publication Publication Date Title
JP2021511363A5 (https=)
JPWO2019147782A5 (https=)
HRP20212000T1 (hr) Aminotriazolopiridini kao inhibitori kinaze
KR101245918B1 (ko) 칸나비노이드 수용체 1 활성의 억제제로서 화합물 및 조성물
JP2008509910A5 (https=)
RU2017124425A (ru) Производные 2,4-диоксо-хиназолин-6-сульфонамида в качестве ингибиторов parg
JP2021535134A5 (https=)
JP2008504275A5 (https=)
JP2018530591A5 (https=)
RU2019117556A (ru) Индазольные производные, пригодные в качестве ингибиторов диацилглицерид o-ацилтрансферазы 2
JP2006516145A5 (https=)
HRP20210143T1 (hr) 2-heteroaril-3-okso-2,3-dihidropiridazin-4-karboksamidi za liječenje raka
JP2019533694A5 (https=)
JP2020502058A5 (https=)
JP2019523266A5 (https=)
JP2016514709A5 (https=)
RU2017125520A (ru) Соединения, ингибирующие parg
CA2507501A1 (en) 3-aminopyrrolidine derivatives as modulators of chemokine receptors
RU2011127402A (ru) Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний
RU2016137674A (ru) Производные пиперидиндиона
CA2469821A1 (en) Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
JP2017522374A5 (https=)
RU2018104868A (ru) 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1
CA2487489A1 (en) Mitotic kinesin inhibitors
HRP20120589T1 (hr) Aktivatori glukokinaze pirolidinona